Tuesday, September 27, 2022

Cannabis-Based Drug Approved For Cancer Treatment In Peru

Sativyl contains a 27 mg/ml concentration of THC (tetrahydrocannabinol) and 25 mg/ml of CBD. It’s sold by the flask and contains 10 ml and 250 mg of concentration.

By Javier Hasse

Cannabis-based drug Sativyl has been approved as a treatment for cancer-related pain in Peru.

Sativyl, produced by Verdemed, was created to be as similar as possible to Sativex, produced by Jazz Pharmaceuticals PLC’s GW Pharmaceuticals and is recommended for the relief of cancer symptoms and spasticity in patients with multiple sclerosis.

breast cancer
Photo by fstop123/Getty Images

Among other uses, Sativyl is indicated to relieve strong pain. The medication is considered an efficient, non-addictive substitute for opioids, like morphine or oxycodone.

In the United States, opioids are considered a public health issue. The CDC recorded a 28.5% increase in deaths caused by opioid overdoses between April 2020 and April 2021. For the first time ever, the country surpassed the mark of 100,000 drug-related deaths over a year-long period.

An Alternative To Classic Antiemetics

Sativyl also works to control nausea caused by chemotherapy treatment. The antiemetic performance of the medication improves the patient’s appetite and, consequently, their physical condition to face the therapy.

Sativyl contains a 27 mg/ml concentration of THC (tetrahydrocannabinol) and 25 mg/ml of CBD. It’s sold by the flask and contains 10 ml and 250 mg of concentration.

RELATED: Breast Cancer Patients Are Using Cannabis, But Many Are Lacking This Important Step

The medicine itself is produced in Canada by the pharmaceutical company Verdemed, in partnership with the Toronto Institute of Pharmaceutical Technology.

THC oil
Photo by Rocky89/Getty Images

“In January of next year, we’ll have Sativyl on the Peruvian market,” says José Bacellar, the company’s CEO. “We believe it will cost a third of Mevatyl [the Brazilian version of Sativex], coming up to a mere R$500 [$89.60].”

RELATED: Cancer Patients Say Cannabis Is Just As Effective Or Better Than Cancer Treatments

The Peruvian health license was approved less than one month after Verdemed received the Brazilian Sanitary Agency (ANVISA) approval to distribute full spectrum 50 mg/ml CBD, a medicine developed in partnership with the American-Colombian company Clever Leaves. Documentation for Sativyl has already been submitted to ANVISA (the Brazilian equivalent of the FDA) for analysis.

This article originally appeared on Benzinga and has been reposted with permission.



Don't Miss Your Weekly Dose of The Fresh Toast.

Stay informed with exclusive news briefs delivered directly to your inbox every Friday.

We respect your privacy. Unsubscribe anytime.